RxDoctor Payments Data

Abhinav Singla, MD

Internal Medicine · Rochester, MNNPI 1104230002

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 54.3% of the total. Among internal medicine clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,101in general payments, 2019–2025

Across 39 payments — averaging $130.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$3K
  • Merck$2K
  • Novartis$101
  • SK Life Science, Inc.$85
  • GSK$65
  • Biohaven Pharmaceuticals, Inc.$57
  • plus $99 from 4 others

What the payments were for

  • Consulting fees$1,75034%
  • Speaking & faculty fees$2,75254%
  • Food & beverage$59912%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,101 in reported general payments places this provider in the 95th percentile of 1,924 internal medicine providers in Minnesota.

See all internal medicine providers in Minnesota

Medicare billing

Part B allowed, 2024
$16,945
Medicare patients
104
Services billed
240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Atorvastatin Calcium13$347
Rosuvastatin Calcium13$92

Paid to pharmacies, not to this prescriber.

Other internal medicine in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →